Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 3:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PROWESS Clear all
Completed Phase 2 Interventional Results available

Prolonged Exposure for Post Traumatic Stress Disorder (PTSD) With/Without Yohimbine

NCT01031979
View directory record Official record
Conditions
Post-Traumatic Stress Disorder
Interventions
Yohimbine, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 45 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Oct 22, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Results available

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

NCT00000620
View directory record Official record
Conditions
Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions
Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 79 Years
Enrollment
10,251 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
6
States / cities
Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 22, 2026, 3:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety

NCT00958880
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Group Cognitive Behavioral Therapy, Yohimbine Hydrochloride, Sugar Pill
Behavioral · Drug
Lead sponsor
Southern Methodist University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
2
States / cities
Boston, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2013 · Synced Oct 22, 2026, 3:53 AM EDT
Completed No phase listed Observational

Studies of Opioid Seeking Behavior: Yohimbine and Hydrocortisone Effects

NCT01536925
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 22, 2026, 3:53 AM EDT
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 22, 2026, 3:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Mifepristone for the Prevention of Relapses of Alcohol Drinking

NCT02243709
View directory record Official record
Conditions
Alcohol Use Disorders (AUD)
Interventions
Mifepristone 600-mg/day or placebo for a week
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 22, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Effect of Yohimbine on Cocaine Cue Reactivity

NCT00535002
View directory record Official record
Conditions
Cocaine Related Disorders
Interventions
Yohimbine, Placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2017 · Synced Oct 22, 2026, 3:53 AM EDT
Completed Phase 2 Interventional

Reserpine for the Treatment of Cocaine Dependence - 1

NCT00033033
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders
Interventions
Reserpine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 99 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
3
States / cities
Boston, Massachusetts • Cincinnati, Ohio • Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 22, 2026, 3:53 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Role Of Sensitivity to neuroEndocrine Systems in Social Decisions

NCT06018727
View directory record Official record
Conditions
Borderline Personality Disorder
Interventions
Hydrocortisone, Yohimbine, Placebo
Drug · Dietary Supplement
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 22, 2026, 3:53 AM EDT
Withdrawn Early Phase 1 Interventional

The Role of the Noradrenergic System in the Nonmotor Symptoms of Parkinson's Disease

NCT04346394
View directory record Official record
Conditions
Parkinson Disease
Interventions
Yohimbine HCl
Drug
Lead sponsor
Nathaniel M. Robbins
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 22, 2026, 3:53 AM EDT
Withdrawn Phase 1 Interventional

A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension

NCT02684786
View directory record Official record
Conditions
Pulmonary Artery Hypertension
Interventions
reserpine, stellate ganglion block, lidocaine
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 22, 2026, 3:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effects of Yohimbine and Naltrexone on Sexual Function

NCT00042536
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Naltrexone HCL/ Yohimbine HCL
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Male only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available

Mechanisms of Refractory Hypertension (Reserpine)

NCT03223272
View directory record Official record
Conditions
Refractory Hypertension
Interventions
Reserpine
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 22, 2026, 3:53 AM EDT
Not listed Phase 1 Interventional

A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine - 1

NCT00267657
View directory record Official record
Conditions
Amphetamine-Related Disorders
Interventions
Reserpine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 22, 2026, 3:53 AM EDT
Not yet recruiting Phase 2 Interventional

Effects of Pharmacological Stress and rTMS on Executive Function in Opioid Use Disorder

NCT04231708
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Yohimbine + Hydrocortisone, Active rTMS, Placebo, Sham rTMS
Drug · Device
Lead sponsor
Wayne State University
Other
Eligibility
21 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 22, 2026, 3:53 AM EDT
Completed Phase 1Phase 2 Interventional

Effects of Buprenorphine/Naloxone Dose on Experimental Stress Reactivity and Opioid Abstinence

NCT03015246
View directory record Official record
Conditions
Heroin Dependence, Opioid Use Disorder
Interventions
Extended release morphine, Buprenorphine/Naloxone low dose, Buprenorphine/Naloxone moderate dose, Buprenorphine/Naloxone high dose, Active stressor, Placebo stressor
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 22, 2026, 3:53 AM EDT
Completed No phase listed Observational

Neurobiological Mechanisms in Panic Disorder

NCT00103987
View directory record Official record
Conditions
Panic Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 60 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 3:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Norepinephrine Levels and Sympathetic Nervous System Activity

NCT00001329
View directory record Official record
Conditions
Autonomic Nervous System Disease, Healthy, Hypertension
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1992 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 3:53 AM EDT
Completed Not applicable Interventional

PROWESS (PROstate Cancer Wearables Exercise and Structured Supports): A Pilot Supportive Care Intervention

NCT05755490
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
PROWESS
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 22, 2026, 3:53 AM EDT
Completed Phase 1Phase 2 Interventional

Effect of Yohimbine on Colon Transit

NCT00217048
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Yohimbine, oral
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 29, 2009 · Synced Oct 22, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available

Modulation of Pharmacologically Induced Alcohol Craving in Recently Detoxified Alcoholics

NCT00605904
View directory record Official record
Conditions
Alcoholism
Interventions
Acamprosate, Yohimbine, mCPP, Saline
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 22, 2026, 3:53 AM EDT
Completed Phase 2 Interventional Results available

Rapid Antidepressant Effects of Yohimbine in Major Depression

NCT00078715
View directory record Official record
Conditions
Depression, Involutional, Major Depresssion
Interventions
Yohimbine hydrochloride, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 22, 2026, 3:53 AM EDT
Completed Phase 1 Interventional

Treatment of Orthostatic Hypotension in Autonomic Failure

NCT00223691
View directory record Official record
Conditions
Autonomic Failure, Orthostatic Hypotension
Interventions
Atomoxetine, Acarbose, Pyridostigmine Bromide, Yohimbine, Midodrine HCl, placebo, Modafinil, Octreotide, water intake, Diphenhydramine Hydrochloride, Ranitidine HCL, Tranylcypromine, Ergotamine/ Caffeine, Celecoxib, Pseudoephedrine, Methylphenidate, Indomethacin, Ibuprofen, Oxymetazoline 0.05% nasal solution, Bovril, Acetazolamide, Rivastigmine tartrate, Carbidopa/levodopa, Inflatable abdominal binder, inflatable abdominal binder (sham)
Drug · Other · Dietary Supplement + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 22, 2026, 3:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Receptors in Sympathetic Nervous System Regulation

NCT00029627
View directory record Official record
Conditions
Healthy
Interventions
Yohimbine
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 3:53 AM EDT